Leerink Partners analyst Mike Kratky has reiterated their neutral stance on EW stock, giving a Hold rating on March 31.
Mike Kratky has given his Hold rating due to a combination of factors influencing Edwards Lifesciences’ current market position. The recent five-year data from Medtronic’s Evolut Low Risk TAVR study suggests that Edwards Lifesciences may experience modest gains. However, the uncertainty surrounding the growth of the U.S. TAVR market, particularly due to capacity constraints, balances the potential risks and rewards, leading to a Hold recommendation.
On the positive side, the competitor data from Medtronic was not as strong as expected, which could be advantageous for Edwards Lifesciences’ SAPIEN valve. This might slow down the loss of market share or even lead to some recovery. Conversely, concerns have been raised about the broader application of TAVR in low-risk patients, particularly due to the increase in all-cause mortality observed in the TAVR arm between years four and five. These mixed signals contribute to the cautious stance reflected in the Hold rating.
In another report released on March 31, TD Cowen also maintained a Hold rating on the stock with a $75.00 price target.
Based on the recent corporate insider activity of 127 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year.